A carregar...
Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()
BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients. We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-do...
Na minha lista:
| Publicado no: | Transl Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Neoplasia Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5491461/ https://ncbi.nlm.nih.gov/pubmed/28666189 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2017.04.008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|